Alterations in the central nervous alpha 2-adrenoceptor system under chronic psychosocial stress. 1996

G Flügge
German Primate Center, Göttingen, Germany.

It has recently been shown for the tree shrew that after 10 days of psychosocial stress, when the central nervous noradrenergic and adrenergic systems are highly activated, alpha 2-adrenoceptors are down-regulated in brain regions which are involved in the regulation of autonomic functions (Flügge G. et al. (1992) Brain Res. 597, 131-137). The present study demonstrates the dynamic changes occurring in the alpha 2-adrenoceptor system during chronic psychosocial stress. Male tree shrews were submitted to psychosocial stress for two, 10, 21 and 28 days, respectively, and alpha 2-adrenoceptor binding characteristics were determined in the locus coeruleus, the prefrontal cortex, the dorsal motor nucleus of the vagus and the solitary tract nucleus by in vitro receptor autoradiography using the antagonist [3H]RX821002 as a ligand. Competition experiments have shown that the radioligand labels the alpha 2-adrenoceptor subtypes A and C in these brain regions. In the locus coeruleus, receptors were already down-regulated two days after the onset of the stress period and stayed low thereafter. In contrast, in the prefrontal cortex, which is innervated by the locus coeruleus, receptor numbers were decreased only on day 10 of psychosocial stress, then returned to control values and were up-regulated from day 28. In the solitary tract nucleus, a down-regulation of alpha 2-adrenoceptors was observed from day 21 of the stress period onwards. The time-course pattern of receptor changes in the dorsal motor nucleus of the vagus followed that of the locus coeruleus. In all cases, changes in receptor numbers did not exceed 17% of the total alpha 2-adrenoceptor number. Besides the changes in receptor numbers, there was a decrease in affinity for the subtype alpha 2A-selective agonists oxymetazoline and UK 14,304, with the strongest effects occurring on day 10 of the stress period. The time-course pattern of these alterations in receptor affinity did not match the time-course pattern in changes of receptor numbers. However, receptor affinities were more or less decreased during the whole period of psychosocial stress. The present findings demonstrate that prolonged periods of recurrent challenging situations induce dynamic changes in the alpha 2-adrenoceptor system leading to region-specific down- or up-regulation of receptors. It is discussed whether the receptor alterations are agonist-mediated or might be due to stress effects on transcription of the receptor genes. The time-dependent alterations indicate that the responsiveness of the receptor system changes with the duration of the stress period, which may have profound consequences for physiological functions subjected to regulation by alpha 2-adrenoceptors.

UI MeSH Term Description Entries
D008125 Locus Coeruleus Bluish-colored region in the superior angle of the FOURTH VENTRICLE floor, corresponding to melanin-like pigmented nerve cells which lie lateral to the PERIAQUEDUCTAL GRAY. Locus Caeruleus Complex,Locus Caeruleus,Locus Ceruleus,Locus Ceruleus Complex,Locus Coeruleus Complex,Nucleus Pigmentosus Pontis,Caeruleus Complex, Locus,Complex, Locus Caeruleus,Complex, Locus Ceruleus,Complex, Locus Coeruleus,Pontis, Nucleus Pigmentosus
D008297 Male Males
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D010109 Oxymetazoline A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251) Oxymetazoline Hydrochloride,Hydrochloride, Oxymetazoline
D010913 Pituitary-Adrenal System The interactions between the anterior pituitary and adrenal glands, in which corticotropin (ACTH) stimulates the adrenal cortex and adrenal cortical hormones suppress the production of corticotropin by the anterior pituitary. Pituitary Adrenal System,Pituitary-Adrenal Systems,System, Pituitary-Adrenal,Systems, Pituitary-Adrenal
D011810 Quinoxalines Quinoxaline
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol
D000068438 Brimonidine Tartrate A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate,5-bromo-6-(imidazolidinylideneamino)quinoxaline,5-bromo-6-(imidazolin-2-ylamino)quinoxaline,AGN 190342,AGN-190342,Alphagan,Alphagan P,Brimonidine,Brimonidine Purite,Brimonidine Tartrate (1:1),Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer,Brimonidine Tartrate, (R-(R*,R*))-Isomer,Bromoxidine,Mirvaso,Ratio-Brimonidine,Sanrosa,UK 14,304,UK 14,304-18,UK 14304,UK 14308,UK-14,304-18,UK-14,308,UK-14304,AGN190342,Ratio Brimonidine,UK 14,304 18,UK 14,30418,UK 14,308,UK14,30418,UK14,308,UK14304

Related Publications

G Flügge
February 1986, Journal of pharmacological methods,
G Flügge
June 1982, Biulleten' eksperimental'noi biologii i meditsiny,
G Flügge
June 1982, Lancet (London, England),
G Flügge
January 1984, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!